Ultrasound technology developed at the Norwegian University of Science and Technology (NTNU) makes it possible to monitor cerebral blood flow in newborn babies, helping prevent brain damage in premature and sick infants who require surgery.
Biohaven’s troriluzole rejected before FDA review
Biohaven said Thursday it received a refusal-to-file letter from the FDA over its NDA for troriluzole in an announcement that sent its share price down